News

To successfully navigate life with myasthenia gravis (MG), people need to be aware of their own bodies and limitations, make proactive plans to set themselves up for success — and, above all, ask for help when it’s needed. “Living with myasthenia gravis independently doesn’t necessarily mean we’re doing everything…

Use of the approved therapy Imaavy (nipocalimab-aahu) leads to a lasting drop in symptoms and related gains in quality of life for adults with generalized myasthenia gravis (gMG) treated early in their disease course, with significant benefits also seen among patients with less severe symptoms at diagnosis. Further,…

Antibodies against the muscle-specific kinase (MuSK) protein may help identify a generally more severe form of myasthenia gravis (MG), one often marked by problems with speech and swallowing and a need for more intensive treatment, a study found. This form of MG varied unexpectedly in frequency among seronegative MG…

UCB’s Rystiggo (rozanolixizumab-noli) and Zilbrysq (zilucoplan) have gained public reimbursement coverage across multiple Canadian provinces for adults with generalized myasthenia gravis (gMG). Product listing agreements are now in place in British Columbia, Québec, Alberta, Saskatchewan, Nova Scotia, and Newfoundland and Labrador for both therapies, and in Ontario…

Vyvgart (efgartigimod alfa-fcab) improves muscle strength and daily functioning in adults with generalized myasthenia gravis (gMG) who are positive for self-reactive antibodies against the acetylcholine receptor (AChR) protein, regardless of patient and disease features or simultaneous treatments. Those are the main findings of a subgroup analysis of data…

The immunosuppressant tacrolimus as a standalone therapy may help adults with mild or moderate myasthenia gravis (MG) reach and maintain a state of minimal disease symptoms (remission), according to a study in China. Patients whose symptoms began at age 70 or younger were significantly more likely to achieve…

Regulators in the U.S. and the European Union have agreed to review applications seeking approval of Regeneron Pharmaceuticals‘ cemdisiran to treat adults with generalized myasthenia gravis (gMG) who have self-reactive antibodies targeting the acetylcholine receptor (AChR) protein. Further, the U.S. Food and Drug Administration (FDA) has granted the application…

The free June 30 webinar was a space to hear patients share practical advice on managing daily life with myasthenia gravis.

A simple model that uses five clinical factors could help doctors predict which people with ocular myasthenia gravis (OMG) are most likely to achieve minimal symptoms or better within one year, according to a study in China. “Based on prognostic predictions, early efforts can be made to develop therapeutic interventions…

Ublituximab-xiiy, an approved medication for certain types of multiple sclerosis (MS), was shown to safely and effectively reduce disease severity in people with myasthenia gravis (MG) who have self-reactive antibodies against the acetylcholine receptor (AChR) protein. That’s according to new data from an early-stage clinical trial that tested the…